Swedish Orphan Biovitrum AB (publ) announced that the EU Commission has approved Xiapex (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis. Xiapex is also approved in the European Union (EU) for the treatment of Dupuytren's contracture in adult patients with a palpable cord.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
265.8 SEK | -4.39% |
|
-6.14% | -0.37% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.37% | 8.97B | |
+7.46% | 100B | |
+8.42% | 42.34B | |
-13.04% | 32.76B | |
+80.42% | 29.46B | |
-10.92% | 16.31B | |
+1.93% | 14.39B | |
-6.77% | 12.23B | |
+177.16% | 10.47B | |
-56.13% | 8.84B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum AB's Xiapex Approves by EU Commission for the Treatment of Peyronie's Disease